Literature DB >> 19171121

The multidrug resistance efflux complex, EmrAB from Escherichia coli forms a dimer in vitro.

Mikio Tanabe1, Gerda Szakonyi, Katherine A Brown, Peter J F Henderson, Jon Nield, Bernadette Byrne.   

Abstract

Tripartite efflux systems are responsible for the export of toxins across both the inner and outer membranes of gram negative bacteria. Previous work has indicated that EmrAB-TolC from Escherichia coli is such a tripartite system, comprised of EmrB an MFS transporter, EmrA, a membrane fusion protein and TolC, an outer membrane channel. The whole complex is predicted to form a continuous channel allowing direct export from the cytoplasm to the exterior of the cell. Little is known, however, about the interactions between the individual components of this system. Reconstitution of EmrA+EmrB resulted in co-elution of the two proteins from a gel filtration column indicating formation of the EmrAB complex. Electron microscopic single particle analysis of the reconstituted EmrAB complex revealed the presence of particles approximately 240x140A, likely to correspond to two EmrAB dimers in a back-to-back arrangement, suggesting the dimeric EmrAB form is the physiological state contrasting with the trimeric arrangement of the AcrAB-TolC system.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19171121     DOI: 10.1016/j.bbrc.2009.01.081

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  25 in total

1.  Identification of Salmonella enterica serovar Pullorum antigenic determinants expressed in vivo.

Authors:  Qiuchun Li; Yachen Hu; Jing Chen; Zhicheng Liu; Jun Han; Lin Sun; Xinan Jiao
Journal:  Infect Immun       Date:  2013-06-17       Impact factor: 3.441

Review 2.  Efflux-mediated drug resistance in bacteria: an update.

Authors:  Xian-Zhi Li; Hiroshi Nikaido
Journal:  Drugs       Date:  2009-08-20       Impact factor: 9.546

Review 3.  Xenobiotic efflux in bacteria and fungi: a genomics update.

Authors:  Ravi D Barabote; Jose Thekkiniath; Richard E Strauss; Govindsamy Vediyappan; Joe A Fralick; Michael J San Francisco
Journal:  Adv Enzymol Relat Areas Mol Biol       Date:  2011

4.  Inverted Regulation of Multidrug Efflux Pumps, Acid Resistance, and Porins in Benzoate-Evolved Escherichia coli K-12.

Authors:  Jeremy P Moore; Haofan Li; Morgan L Engmann; Katarina M Bischof; Karina S Kunka; Mary E Harris; Anna C Tancredi; Frederick S Ditmars; Preston J Basting; Nadja S George; Arvind A Bhagwat; Joan L Slonczewski
Journal:  Appl Environ Microbiol       Date:  2019-08-01       Impact factor: 4.792

Review 5.  Molecular architecture of the bacterial tripartite multidrug efflux pump focusing on the adaptor bridging model.

Authors:  Saemee Song; Jin-Sik Kim; Kangseok Lee; Nam-Chul Ha
Journal:  J Microbiol       Date:  2015-05-30       Impact factor: 3.422

Review 6.  The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria.

Authors:  Xian-Zhi Li; Patrick Plésiat; Hiroshi Nikaido
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

Review 7.  Strategic Moves of "Superbugs" Against Available Chemical Scaffolds: Signaling, Regulation, and Challenges.

Authors:  Bikash Baral; M R Mozafari
Journal:  ACS Pharmacol Transl Sci       Date:  2020-04-13

8.  Structure, Assembly, and Function of Tripartite Efflux and Type 1 Secretion Systems in Gram-Negative Bacteria.

Authors:  Ilyas Alav; Jessica Kobylka; Miriam S Kuth; Klaas M Pos; Martin Picard; Jessica M A Blair; Vassiliy N Bavro
Journal:  Chem Rev       Date:  2021-04-28       Impact factor: 60.622

9.  Mycobacterium smegmatis MSMEG_3705 encodes a selective major facilitator superfamily efflux pump with multiple roles.

Authors:  Zhen Zhang; Rui Wang; Jianping Xie
Journal:  Curr Microbiol       Date:  2015-02-20       Impact factor: 2.188

10.  Modulation of the conformational state of the SV2A protein by an allosteric mechanism as evidenced by ligand binding assays.

Authors:  V Daniels; M Wood; K Leclercq; R M Kaminski; M Gillard
Journal:  Br J Pharmacol       Date:  2013-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.